Pathstone Family Office’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History
Bought
Maintained
Sold
Other funds holding HZNP
Pathstone Family Office's HZNP Position: Q3 2023 in Review
Pathstone Family Office opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2023: 2,355 shares worth $272K. The stake represents ﹤0.01% of the portfolio and ranks #1357 among its holdings. This is a return to the name: Pathstone Family Office previously reported a position in HZNP as recently as Q1 2017.
Pathstone Family Office first reported a position in HZNP in Q1 2017 and has held it in 2 quarters since. 485 funds tracked by Wall St. Rank hold HZNP as of Q3 2023.
- Pathstone Family Office held 2,355 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $272K as of Q3 2023.
- Horizon Therapeutics Public Limited Company Ordinary Shares was a new Pathstone Family Office position in Q3 2023.
- Horizon Therapeutics Public Limited Company Ordinary Shares made up ﹤0.01% of Pathstone Family Office's portfolio in Q3 2023, its #1357 holding.
- Pathstone Family Office first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2017 and has held it in 2 quarters since.
- 485 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2023.
Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.